Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.8%

35 terminated/withdrawn out of 734 trials

Success Rate

89.4%

+2.9% vs industry average

Late-Stage Pipeline

19%

139 trials in Phase 3/4

Results Transparency

5%

14 of 294 completed trials have results

Key Signals

91 recruiting14 with results28 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 1
329(45.3%)
Phase 2
248(34.1%)
Phase 3
130(17.9%)
N/A
11(1.5%)
Phase 4
9(1.2%)
727Total
Phase 1(329)
Phase 2(248)
Phase 3(130)
N/A(11)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (734)

Showing 20 of 734 trials
NCT06091748Phase 3Completed

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Role: lead

NCT06974929Phase 1Recruiting

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

Role: lead

NCT06568094Phase 1Recruiting

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Role: lead

NCT07556822Phase 1Recruiting

Phase I Study of HRS-3005 in B-cell Malignancies

Role: lead

NCT06596876Phase 3Completed

A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

Role: lead

NCT05363800Phase 1Active Not Recruiting

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Role: lead

NCT04621669Phase 1Completed

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Role: lead

NCT07472725Phase 2Active Not Recruiting

A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents

Role: lead

NCT06710990Phase 1Completed

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Role: lead

NCT06688123Phase 2Completed

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

Role: lead

NCT07036419Phase 2Completed

A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients

Role: lead

NCT07404579Phase 2Completed

Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults

Role: lead

NCT07610148Phase 1Not Yet Recruiting

A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants

Role: lead

NCT06587061Phase 2Recruiting

HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Role: collaborator

NCT07131514Phase 2Recruiting

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Role: collaborator

NCT06427239Phase 1Recruiting

Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT05147259Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject

Role: lead

NCT05292495Phase 1Completed

A Trial of HR17031 Injection With Renal Insufficiency

Role: lead

NCT05099848Phase 2Completed

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Role: collaborator

NCT05277168Phase 1Recruiting

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Role: lead